|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
|
JPS6023084B2
(ja)
|
1979-07-11 |
1985-06-05 |
味の素株式会社 |
代用血液
|
|
US4714681A
(en)
|
1981-07-01 |
1987-12-22 |
The Board Of Reagents, The University Of Texas System Cancer Center |
Quadroma cells and trioma cells and methods for the production of same
|
|
US4474893A
(en)
|
1981-07-01 |
1984-10-02 |
The University of Texas System Cancer Center |
Recombinant monoclonal antibodies
|
|
US4640835A
(en)
|
1981-10-30 |
1987-02-03 |
Nippon Chemiphar Company, Ltd. |
Plasminogen activator derivatives
|
|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4496689A
(en)
|
1983-12-27 |
1985-01-29 |
Miles Laboratories, Inc. |
Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
|
|
JPS6147500A
(ja)
|
1984-08-15 |
1986-03-07 |
Res Dev Corp Of Japan |
キメラモノクロ−ナル抗体及びその製造法
|
|
EP0173494A3
(en)
|
1984-08-27 |
1987-11-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chimeric receptors by dna splicing and expression
|
|
GB8422238D0
(en)
|
1984-09-03 |
1984-10-10 |
Neuberger M S |
Chimeric proteins
|
|
JPS61134325A
(ja)
|
1984-12-04 |
1986-06-21 |
Teijin Ltd |
ハイブリツド抗体遺伝子の発現方法
|
|
US4751180A
(en)
|
1985-03-28 |
1988-06-14 |
Chiron Corporation |
Expression using fused genes providing for protein product
|
|
EP0206448B1
(en)
|
1985-06-19 |
1990-11-14 |
Ajinomoto Co., Inc. |
Hemoglobin combined with a poly(alkylene oxide)
|
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
|
DE3689123T2
(de)
|
1985-11-01 |
1994-03-03 |
Xoma Corp |
Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
|
|
US4935233A
(en)
|
1985-12-02 |
1990-06-19 |
G. D. Searle And Company |
Covalently linked polypeptide cell modulators
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
|
US4791192A
(en)
|
1986-06-26 |
1988-12-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified protein with polyethyleneglycol
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・2・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US5364858A
(en)
|
1987-03-31 |
1994-11-15 |
Research Triangle Institute |
Camptothecin analogs as potent inhibitors of topoisomerase I
|
|
US4925648A
(en)
|
1988-07-29 |
1990-05-15 |
Immunomedics, Inc. |
Detection and treatment of infectious and inflammatory lesions
|
|
US5601819A
(en)
|
1988-08-11 |
1997-02-11 |
The General Hospital Corporation |
Bispecific antibodies for selective immune regulation and for selective immune cell binding
|
|
EP0401384B1
(en)
|
1988-12-22 |
1996-03-13 |
Kirin-Amgen, Inc. |
Chemically modified granulocyte colony stimulating factor
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5166322A
(en)
|
1989-04-21 |
1992-11-24 |
Genetics Institute |
Cysteine added variants of interleukin-3 and chemical modifications thereof
|
|
EP0739904A1
(en)
|
1989-06-29 |
1996-10-30 |
Medarex, Inc. |
Bispecific reagents for aids therapy
|
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
|
DK0553244T4
(da)
|
1990-10-05 |
2005-08-01 |
Celldex Therapeutics Inc |
Målrettet immunostimulering med bispecifikke reagenser
|
|
AU8727291A
(en)
|
1990-10-29 |
1992-06-11 |
Cetus Oncology Corporation |
Bispecific antibodies, method of production, and uses thereof
|
|
EP0582595A1
(en)
|
1991-04-26 |
1994-02-16 |
Surface Active Limited |
Novel antibodies, and methods for their use
|
|
EP0590058B1
(en)
|
1991-06-14 |
2003-11-26 |
Genentech, Inc. |
HUMANIZED Heregulin ANTIBODy
|
|
US5559235A
(en)
|
1991-10-29 |
1996-09-24 |
Glaxo Wellcome Inc. |
Water soluble camptothecin derivatives
|
|
DK0540099T3
(da)
|
1991-10-29 |
1996-06-17 |
Glaxo Wellcome Inc |
Vandopløselige camptothecinderivater
|
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
|
EP0556585A3
(en)
|
1992-01-24 |
1993-09-01 |
Takeda Chemical Industries, Ltd. |
Condensed camptothecin derivatives their production and use as antitumor agents
|
|
GB9203459D0
(en)
|
1992-02-19 |
1992-04-08 |
Scotgen Ltd |
Antibodies with germ-line variable regions
|
|
EP1306095A3
(en)
|
1992-03-05 |
2003-06-25 |
Board Of Regents, The University Of Texas System |
Methods and compositions for targeting the vasculature of solid tumors
|
|
US5342947A
(en)
|
1992-10-09 |
1994-08-30 |
Glaxo Inc. |
Preparation of water soluble camptothecin derivatives
|
|
PT672141E
(pt)
|
1992-10-23 |
2003-09-30 |
Immunex Corp |
Metodos de preparacao de proteinas oligomericas soluveis
|
|
US5496630A
(en)
|
1993-09-13 |
1996-03-05 |
The Geon Company |
Thermoplastic multilayer louver with a polished metal look
|
|
US5496830A
(en)
|
1994-09-14 |
1996-03-05 |
Johns Hopkins University |
Inhibition of hemoflagellates by camptothecin compounds
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
JP2763020B2
(ja)
|
1995-04-27 |
1998-06-11 |
日本電気株式会社 |
半導体パッケージ及び半導体装置
|
|
US5672662A
(en)
|
1995-07-07 |
1997-09-30 |
Shearwater Polymers, Inc. |
Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
|
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
|
CA2249195A1
(en)
|
1996-03-18 |
1997-09-25 |
Board Of Regents, The University Of Texas System |
Immunoglobin-like domains with increased half lives
|
|
US5834597A
(en)
|
1996-05-20 |
1998-11-10 |
Protein Design Labs, Inc. |
Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
|
|
EP1731174A3
(en)
|
1996-08-02 |
2007-01-17 |
Ortho-McNeil Pharmaceutical, Inc. |
Polypeptides having a covalently bound N-terminal polyethylene glycol via hydrazone or oxime bond
|
|
SG88737A1
(en)
|
1996-10-30 |
2002-05-21 |
Tanabe Seiyaku Co |
S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof
|
|
JP2002506353A
(ja)
|
1997-06-24 |
2002-02-26 |
ジェネンテック・インコーポレーテッド |
ガラクトシル化糖タンパク質の方法及び組成物
|
|
CA2307166A1
(en)
|
1997-10-31 |
1999-05-14 |
Genentech, Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
|
WO1999029888A1
(en)
|
1997-12-05 |
1999-06-17 |
The Scripps Research Institute |
Humanization of murine antibody
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
CA2323757C
(en)
|
1998-04-02 |
2011-08-02 |
Genentech, Inc. |
Antibody variants and fragments thereof
|
|
JP4334141B2
(ja)
|
1998-04-20 |
2009-09-30 |
グリカート バイオテクノロジー アクチェンゲゼルシャフト |
抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
HUP0104865A3
(en)
|
1999-01-15 |
2004-07-28 |
Genentech Inc |
Polypeptide variants with altered effector function
|
|
MY128897A
(en)
|
1999-02-05 |
2007-02-28 |
Samsung Electronics Co Ltd |
Image texture retrieving method and apparatus thereof
|
|
EP2275540B1
(en)
|
1999-04-09 |
2016-03-23 |
Kyowa Hakko Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
|
EE200100603A
(et)
|
1999-05-14 |
2003-02-17 |
Imclone Systems Incorporated |
Inimese refraktaarsete kasvajate ravi epidermaalse kasvufaktori retseptori antagonistidega
|
|
CA2388245C
(en)
|
1999-10-19 |
2012-01-10 |
Kyowa Kirin Co., Ltd. |
The use of serum-free adapted rat cells for producing heterologous polypeptides
|
|
US6629995B1
(en)
|
2000-03-31 |
2003-10-07 |
Super Gen, Inc. |
Camptothecin conjugates
|
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
|
CN103333860B
(zh)
|
2000-10-06 |
2015-07-08 |
协和发酵麒麟株式会社 |
产生抗体组合物的细胞
|
|
US6825206B1
(en)
|
2000-11-16 |
2004-11-30 |
Research Triangle Institute |
Camptothecin compounds with a thioether group
|
|
US7090843B1
(en)
|
2000-11-28 |
2006-08-15 |
Seattle Genetics, Inc. |
Recombinant anti-CD30 antibodies and uses thereof
|
|
AU2002368077B2
(en)
|
2001-07-12 |
2010-03-04 |
Jefferson Foote |
Super humanized antibodies
|
|
EP1423510A4
(en)
|
2001-08-03 |
2005-06-01 |
Glycart Biotechnology Ag |
ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
|
|
PL213948B1
(pl)
|
2001-10-25 |
2013-05-31 |
Genentech Inc |
Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
|
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
|
US8877901B2
(en)
|
2002-12-13 |
2014-11-04 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
|
US7591994B2
(en)
|
2002-12-13 |
2009-09-22 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
|
WO2003085102A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
|
|
WO2003084570A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
|
|
CA2481920A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Antibody composition-containing medicament
|
|
EP1498491A4
(en)
|
2002-04-09 |
2006-12-13 |
Kyowa Hakko Kogyo Kk |
METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
|
|
EP1498490A4
(en)
|
2002-04-09 |
2006-11-29 |
Kyowa Hakko Kogyo Kk |
PROCESS FOR PREPARING ANTIBODY COMPOSITION
|
|
KR20050000380A
(ko)
|
2002-04-09 |
2005-01-03 |
교와 핫꼬 고교 가부시끼가이샤 |
게놈이 개변된 세포
|
|
ES2369542T3
(es)
|
2002-07-31 |
2011-12-01 |
Seattle Genetics, Inc. |
Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
|
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
HUE035898T2
(en)
|
2002-12-16 |
2018-05-28 |
Genentech Inc |
Immunoglobulin variants and their applications
|
|
JPWO2005035586A1
(ja)
|
2003-10-08 |
2007-11-22 |
協和醗酵工業株式会社 |
融合蛋白質組成物
|
|
CA2542125A1
(en)
|
2003-10-09 |
2005-04-21 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase
|
|
HUE038955T2
(hu)
|
2003-11-05 |
2018-12-28 |
Roche Glycart Ag |
Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
|
|
ES2605443T3
(es)
|
2003-11-06 |
2017-03-14 |
Seattle Genetics, Inc. |
Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
|
|
JPWO2005053742A1
(ja)
|
2003-12-04 |
2007-06-28 |
協和醗酵工業株式会社 |
抗体組成物を含有する医薬
|
|
CA2556752C
(en)
|
2004-02-23 |
2016-02-02 |
Genentech, Inc. |
Heterocyclic self-immolative linkers and conjugates
|
|
CN1961003B
(zh)
|
2004-03-31 |
2013-03-27 |
健泰科生物技术公司 |
人源化抗TGF-β抗体
|
|
ITMI20041427A1
(it)
|
2004-07-15 |
2004-10-15 |
Univ Degli Studi Milano |
Sintesi di molecole organometalliche utilizzabili come marcatori di sostanze organiche
|
|
AU2005290250A1
(en)
|
2004-07-30 |
2006-04-06 |
Rinat Neuroscience Corp. |
Antibodies directed against amyloid-beta peptide and methods using same
|
|
TR201808537T4
(tr)
|
2004-09-23 |
2018-07-23 |
Genentech Inc |
Sistein değiştirilmiş antikorlar ve konjugatlar.
|
|
JP2008519863A
(ja)
|
2004-11-12 |
2008-06-12 |
シアトル ジェネティクス インコーポレイティッド |
N末端にアミノ安息香酸単位を有するオーリスタチン
|
|
US8067546B2
(en)
|
2005-04-19 |
2011-11-29 |
Seattle Genetics, Inc. |
Humanized anti-CD70 binding agents and uses thereof
|
|
US20070116643A1
(en)
|
2005-07-01 |
2007-05-24 |
Concert Pharmaceuticals Inc. |
Novel aryloxypropanamines
|
|
WO2007005643A2
(en)
|
2005-07-01 |
2007-01-11 |
Concert Pharmaceuticals Inc. |
Novel aryloxyphenylpropanamines
|
|
US7923538B2
(en)
|
2005-07-22 |
2011-04-12 |
Kyowa Hakko Kirin Co., Ltd |
Recombinant antibody composition
|
|
CA2616366A1
(en)
|
2005-07-29 |
2007-02-08 |
Concert Pharmaceuticals Inc. |
Novel pharmaceutical compounds
|
|
CN101273024A
(zh)
|
2005-07-29 |
2008-09-24 |
康瑟特制药公司 |
新颖苯并[d][1,3]-二氧杂环戊烯衍生物
|
|
JP4860703B2
(ja)
|
2005-10-06 |
2012-01-25 |
ゼンコー・インコーポレイテッド |
最適化された抗cd30抗体
|
|
US7750116B1
(en)
|
2006-02-18 |
2010-07-06 |
Seattle Genetics, Inc. |
Antibody drug conjugate metabolites
|
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
|
CA2676529C
(en)
|
2007-01-24 |
2014-03-25 |
Kyowa Kirin Co., Ltd. |
Genetically recombinant antibody composition having enhanced effector activity
|
|
US8038273B2
(en)
|
2007-03-27 |
2011-10-18 |
Lexmark International, Inc. |
Ink tank venting
|
|
KR101641345B1
(ko)
|
2007-10-12 |
2016-07-20 |
시애틀 지네틱스, 인크. |
항체-약물 접합체를 이용한 병용 요법
|
|
CN101903403B
(zh)
|
2007-10-19 |
2016-03-16 |
西雅图基因公司 |
Cd19结合剂及其应用
|
|
EP3663318A1
(en)
|
2008-01-07 |
2020-06-10 |
Amgen Inc. |
Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
|
|
US8293714B2
(en)
|
2008-05-05 |
2012-10-23 |
Covx Technology Ireland, Ltd. |
Anti-angiogenic compounds
|
|
WO2010081004A1
(en)
|
2009-01-09 |
2010-07-15 |
Seattle Genetics, Inc. |
Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
|
|
ES2874306T3
(es)
|
2010-09-29 |
2021-11-04 |
Agensys Inc |
Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12
|
|
CN102850400A
(zh)
|
2011-06-30 |
2013-01-02 |
周文强 |
喜树碱衍生物及其制备方法、药物组合物与用途
|
|
EP2589609A1
(en)
|
2011-11-03 |
2013-05-08 |
Pierre Fabre Medicament |
Antigen binding protein and its use as addressing product for the treatment of cancer
|
|
CN104822656B
(zh)
|
2012-05-15 |
2018-05-01 |
西雅图基因公司 |
自稳定接头偶联物
|
|
US9504756B2
(en)
|
2012-05-15 |
2016-11-29 |
Seattle Genetics, Inc. |
Self-stabilizing linker conjugates
|
|
TR201900694T4
(tr)
|
2012-08-23 |
2019-02-21 |
Agensys Inc |
158p1d7 proteinlerine bağlanan antikor ilaç konjugatları (adc).
|
|
US20140099256A1
(en)
|
2012-08-28 |
2014-04-10 |
The Board Of Regents Of The University Of Texas System |
Radioactive luminescent nanoparticle compositions
|
|
PT3199552T
(pt)
|
2012-11-20 |
2020-03-25 |
Sanofi Sa |
Anticorpos anti-ceacam5 e suas utilizações
|
|
HK1220698A1
(zh)
|
2013-03-13 |
2017-05-12 |
Seattle Genetics, Inc. |
环糊精和抗体药物偶联物制剂
|
|
US20160106861A1
(en)
|
2013-04-26 |
2016-04-21 |
Spirogen Sarl |
Axl antibody-drug conjugate and its use for the treatment of cancer
|
|
US11229711B2
(en)
*
|
2013-06-06 |
2022-01-25 |
Magenta Therapeutics, Inc. |
Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
|
|
PT3057585T
(pt)
|
2013-10-15 |
2020-10-21 |
Seagen Inc |
Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando
|
|
CN105813653B
(zh)
*
|
2013-12-19 |
2020-06-26 |
西雅图基因公司 |
与目标-药物偶联物并用的亚甲基氨基甲酸酯连接物
|
|
EP3125943B1
(en)
*
|
2014-04-04 |
2026-04-22 |
Merck Sharp & Dohme LLC |
Phosphate based linkers for intracellular delivery of drug conjugates
|
|
TWI871999B
(zh)
|
2014-04-10 |
2025-02-01 |
日商第一三共股份有限公司 |
抗her3抗體-藥物結合物
|
|
EP3229844B1
(en)
*
|
2014-12-09 |
2020-03-04 |
AbbVie Inc. |
Antibody drug conjugates with cell permeable bcl-xl inhibitors
|
|
JP2018502839A
(ja)
*
|
2014-12-09 |
2018-02-01 |
アッヴィ・インコーポレイテッド |
Bcl−xL阻害性化合物およびこれを含む抗体薬物コンジュゲート
|
|
KR20170128256A
(ko)
|
2015-03-18 |
2017-11-22 |
시애틀 지네틱스, 인크. |
Cd48 항체 및 이의 접합체
|
|
TW201709932A
(zh)
|
2015-06-12 |
2017-03-16 |
西雅圖遺傳學公司 |
Cd123抗體及其共軛物
|
|
KR20180021705A
(ko)
|
2015-06-30 |
2018-03-05 |
시애틀 지네틱스, 인크. |
항-ntb-a 항체 및 관련 조성물 및 방법
|
|
EP3433278A4
(en)
|
2016-03-25 |
2019-11-06 |
Seattle Genetics, Inc. |
METHOD FOR THE PRODUCTION OF PEGYLATED ACTIVE LINKERS AND INTERMEDIATE PRODUCTS THEREOF
|
|
MX390955B
(es)
|
2016-06-02 |
2025-03-19 |
Seagen Inc |
Uso de un anticuerpo anti-pd-1 en combinación con un anticuerpo anti-cd30 para el tratamiento de linfoma.
|
|
KR20240010534A
(ko)
|
2016-08-09 |
2024-01-23 |
씨젠 인크. |
개선된 물리화학적 특성을 갖는 자기 안정화 링커를 구비한 약물 접합체
|
|
US20200247902A1
(en)
|
2016-11-17 |
2020-08-06 |
Seattle Genetics, Inc. |
Compositions and methods for treating cancer
|
|
JP7244987B2
(ja)
*
|
2016-12-14 |
2023-03-23 |
シージェン インコーポレイテッド |
多剤抗体薬物コンジュゲート
|
|
KR20240044544A
(ko)
|
2017-03-03 |
2024-04-04 |
씨젠 인크. |
글리칸-상호작용 화합물 및 사용 방법
|
|
MA50369A
(fr)
|
2017-10-13 |
2020-08-19 |
Seattle Genetics Inc |
Modulation de la réponse immunitaire à l'aide de conjugués anticorps-médicament
|
|
KR20200080274A
(ko)
|
2017-11-01 |
2020-07-06 |
시애틀 지네틱스, 인크. |
항-cd30 항체 약물 컨쥬게이트 요법의 부작용을 감소시키는 방법
|
|
CA3084495A1
(en)
|
2017-12-01 |
2019-06-06 |
Seattle Genetics, Inc. |
Humanized anti-liv1 antibodies for the treatment of breast cancer
|
|
CN111936169A
(zh)
|
2018-04-06 |
2020-11-13 |
西雅图遗传学公司 |
喜树碱肽缀合物
|
|
TWI920652B
(zh)
|
2018-06-07 |
2026-04-01 |
美商思進公司 |
喜樹鹼結合物
|
|
MX2021003734A
(es)
|
2018-10-01 |
2021-07-16 |
Seagen Inc |
Métodos de tratamiento del linfoma de linfocitos t periférico mediante terapia con conjugado fármaco-anticuerpo anti-cd30.
|
|
KR20210124260A
(ko)
|
2019-02-07 |
2021-10-14 |
사노피 |
폐암을 치료하기 위한 항-ceacam5 면역접합체의 용도
|
|
AU2020348876A1
(en)
|
2019-09-19 |
2022-04-07 |
Seagen Inc. |
Selective drug release from internalized conjugates of biologically active compounds
|
|
WO2021067820A1
(en)
|
2019-10-04 |
2021-04-08 |
Seagen Inc. |
Formulation of antibody-drug conjugate
|
|
KR20220079606A
(ko)
|
2019-10-04 |
2022-06-13 |
씨젠 인크. |
캄프토테신 펩티드 접합체
|
|
CN115427082A
(zh)
|
2020-04-24 |
2022-12-02 |
赛诺菲 |
含有抗ceacam5抗体缀合物和folfox的抗肿瘤组合
|
|
CA3181000A1
(en)
|
2020-04-24 |
2021-10-28 |
Sanofi |
Antitumor combinations containing anti-ceacam5 antibody conjugates and folfiri
|
|
EP4138925A1
(en)
|
2020-04-24 |
2023-03-01 |
Sanofi |
Antitumor combinations containing anti-ceacam5 antibody conjugates, trifluridine and tipiracil
|
|
BR112022020477A2
(pt)
|
2020-04-24 |
2022-11-29 |
Sanofi Sa |
Combinações antitumor contendo conjugados de anticorpo anti-ceacam5 e cetuximabe
|
|
KR20230023650A
(ko)
|
2020-05-13 |
2023-02-17 |
씨젠 인크. |
항-cd30 항체-약물 컨쥬게이트의 조합을 사용하여 암을 치료하는 방법
|
|
US20250122282A2
(en)
|
2020-09-04 |
2025-04-17 |
Merck Patent Gmbh |
Anti-ceacam5 antibodies and conjugates and uses thereof
|
|
JP7849358B2
(ja)
|
2020-11-10 |
2026-04-21 |
サノフイ |
Ceacam5抗体-薬物コンジュゲート製剤
|
|
CA3203777A1
(en)
|
2020-12-03 |
2022-06-09 |
Seagen Inc. |
Modulating the immune response using anti-cd30 antibody-drug conjugates
|
|
IL305886A
(en)
|
2021-03-18 |
2023-11-01 |
Seagen Inc |
Selective release of drugs from internalized conjugates of biologically active compounds
|
|
JP2024510435A
(ja)
|
2021-03-18 |
2024-03-07 |
シージェン インコーポレイテッド |
生体活性化合物の内部移行複合体からの選択的薬物放出
|
|
AU2022382383A1
(en)
|
2021-11-05 |
2024-06-20 |
Eli Lilly And Company |
Antitumor combinations containing anti-ceacam5 antibody-drug conjugates and anti-vegfr-2 antibodies
|
|
MX2024006766A
(es)
|
2021-12-02 |
2024-07-29 |
Sanofi Sa |
Prueba de cea para la selección de pacientes en tratamiento del cáncer.
|
|
KR20250004952A
(ko)
*
|
2022-03-17 |
2025-01-08 |
씨젠 인크. |
캄프토테신 접합체
|
|
WO2024108053A1
(en)
|
2022-11-17 |
2024-05-23 |
Sanofi |
Ceacam5 antibody-drug conjugates and methods of use thereof
|